With a U.S. judge refusing to grant an injunction against generic versions of it’s top-selling drug Seroquel last Friday, the Wall Street Journal reports that AstraZeneca is struggling to control costs and find acquisitions that will help it to exploit new product lines. The decision follows the U.K. High Court’s decision last week that AstraZeneca’s patent on Seroquel is invalid in Britain.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.